Doximity stock
DOCSNYSEDoximity, Inc., HealthcareISIN US26622P1075
81Score 81 out of 100, Strong
Price and trend
82 / 100
Price history
−35% in one yearThe chart shows daily closes over 5 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 32% above it.
Since October 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 49).
The price is 36% below its 52-week high. Largest decline in 5 years: 82% (September 2021 to May 2026).
Chart figures for advanced users
- SMA 50$29.61
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$25.22
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)49
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$18.01
- The lowest closing price of the last twelve months.
- Resistance$51.53
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Doximity, Inc. belongs to the Medical (Healthcare Information Services) industry (United States) and, with a market value of $5.92B, is number 7 of 25 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $644.86M (up 13.1% year on year) and earnings of $196.05M (down 12.2%).
- For fiscal 2027, analysts expect on average revenue of $677.59M (up 5.1%) and adjusted earnings per share of $1.35 (down 12%).
Show more
- MEQIRI Score 81 out of 100 (Strong): rank 14 of 714 in Healthcare, median 53.
- The P/E is 44.6 (Medical (Healthcare Information Services) median 43, own median of recent years 48.8).
- Our model puts fair value at $32.16, with the price 3% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 86% in fiscal 2026, Medical (Healthcare Information Services) median 1.2%.Profitability 88
- Earnings per share growingUp 54.3% a year since 2021.Growth 99
- Growing faster than its industryRevenue up 25.5% a year since 2021, Medical (Healthcare Information Services) median 16.5%.Growth 99
Weaknesses
- Volatile share priceVolatility 63% a year over the last 12 months.
- Share price fell sharplyDown 37% over the last 12 months.Momentum 58
Its standout strengths are fundamentals and growth, while valuation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- high growth grade (crashed more often in the backtest)
- price far below its 52-week high
What lowers it
- solid fundamentals
- price not overheated over the past year
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $21.44 and expensive above $64.33 (uncertainty very high, based on the price swings of the past year).
The two parts of the fair value come to $32.32 (cash-flow model) and $32.00 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is slightly above both parts; given how much the stock swings, that still counts as fair.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $29.40, at 7.8% it would be $36.32.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (43).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 6.5% on the twelve months before. Revenue has grown strongly since 2019, at around 33% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 89%, operating 33%, net 30%. Last 12 months: net 21%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 4 Feb 2027in 84 days
- Last reported
- 5 Nov 2026EPS reported $0.36 (expected $0.35)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $1.350.0%
- Revenue
- $677.59M0.0%
- Earnings per share
- $1.56+0.1%
- Revenue
- $721.94M−0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +26.7%Outlook raised by slightly more than the quarterly beat: fiscal 2027 adjusted EBITDA now $309 million to $329 million, with higher AI spending.
“For fiscal '27, we now expect a revised range of $309 million to $329 million, representing a 47% adjusted EBITDA margin at the midpoint.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q1 2027), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $1.2M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Cabral Timothy SSale
5 Nov 2026, Board
- Shares
- 10,721
- Price
- $35.00
- Value
- $375,235
- Wampler Kira SchererSale
2 Nov 2026, Board
- Shares
- 2,000
- Price
- $32.89
- Value
- $65,780
- Sitaram SiddharthSale
14 Oct 2026, Chief Accounting Officer
- Shares
- 2,613
- Price
- $30.68
- Value
- $80,167
Show 9 more
- Wampler Kira SchererSale
1 Oct 2026, Board
- Shares
- 2,000
- Price
- $28.91
- Value
- $57,820
- Yang Watkin Phoebe L.Sale
30 Sept 2026, Board
- Shares
- 1,290
- Price
- $26.71
- Value
- $34,456
- Sitaram SiddharthSale
15 Sept 2026, Chief Accounting Officer
- Shares
- 2,077
- Price
- $26.02
- Value
- $54,044
- Wampler Kira SchererSale
1 Sept 2026, Board
- Shares
- 2,000
- Price
- $26.33
- Value
- $52,660
- Wampler Kira SchererSale
25 Aug 2026, Board
- Shares
- 2,000
- Price
- $24.95
- Value
- $49,900
- Sitaram SiddharthSale
13 Aug 2026, Chief Accounting Officer
- Shares
- 1,770
- Price
- $24.94
- Value
- $44,144
- Cabral Timothy SSale
7 Aug 2026, Board
- Shares
- 7,500
- Price
- $39.11
- Value
- $293,325
- Sitaram SiddharthSale
15 Jul 2026, Chief Accounting Officer
- Shares
- 1,732
- Price
- $22.02
- Value
- $38,139
- Sitaram SiddharthSale
8 Jun 2026, Interim PAO
- Shares
- 2,444
- Price
- $20.41
- Value
- $49,882
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Doximity
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 81
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Information Services)
The next larger and next smaller companies by market value
- Hinge HealthHNGE $9.82B70
- HealthEquityHQY $8.52B71
- M32413.T $7.7B73
- Alibaba Health Information Technology0241.HK $6.19B60
- Waystar HoldingWAY $5.55B60
- HeartflowHTFL $5.14B46
- Privia Health GroupPRVA $3.07B58
- CertaraCERT $1.79B54
ETFs that hold Doximity
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 4.46% | 0.68% | €5.31M |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.13% | 0.30% | €5.27B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.06% | 0.43% | €2.48B |
Show 5 more
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.04% | 0.35% | €434.1M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.04% | 0.35% | €8.19B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.03% | 0.30% | €944.34M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.01% | 0.25% | €175.89M |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 30 Nov 2022)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.